Substance / Medication

Amphotericin B liposome

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

14 trials linked to this intervention

14
Total Trials
1
Recruiting
2
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Gender differences in acute toxicity, toxicokinetic and tissue distribution of amphotericin B liposomes in rats.
Wang Dong, Zhang Wei, Ju Jie-Xi et al. · Toxicol Lett · 2021
PMID: 33309996Observational
Stability and transdermal absorption of topical amphotericin B liposome formulations.
Manosroi A, Kongkaneramit L, Manosroi J · Int J Pharm · 2004
PMID: 14726142Observational
Voriconazole combined with low-dose amphotericin B liposome for treatment of cryptococcal meningitis.
Li Shan-Shan, Tang Xin-Yue, Zhang Sheng-Guo et al. · Infect Dis (Lond) · 2016
PMID: 27044559Case Report
[Life saving treatment using amphotericin B liposome for a case with fungal meningitis due to orbital cellulitis].
Kurita Naoki, Okoshi Yasushi, Nakamoto Rie et al. · Jpn J Antibiot · 2011
PMID: 21786482Case Report
C-reactive protein interacts with amphotericin B liposomes and its potential clinical consequences.
Delanghe Joris R, Himpe Jonas, Boelens Jerina et al. · Clin Chem Lab Med · 2023
PMID: 36691951Other
Development of a flow-through USP 4 apparatus drug release assay for the evaluation of amphotericin B liposome.
Tang Jie, Srinivasan Santhanakrishnan, Yuan Wenmin et al. · Eur J Pharm Biopharm · 2019
PMID: 30481559Other
[Treatment strategy using amphotericin B liposome for cases of fungal pneumonia associated with hematological malignancy].
Uchiyama Norihiro, Ikeda Utsugi, Murata Takeshi · Jpn J Antibiot · 2011
PMID: 21786481Other
Identification of a microglial activation-dependent antidepressant effect of amphotericin B liposome.
Gao Minhui, Hu Peili, Cai Zixuan et al. · Neuropharmacology · 2019
PMID: 30954529Preclinical
Investigations on feasibility of in situ development of amphotericin B liposomes for industrial applications.
Singodia Deepak, Verma Ashwni, Khare Prashant et al. · J Liposome Res · 2012
PMID: 21682670Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Amphotericin B liposome (substance)
SNOMED CT
412088006
UMLS CUI
C1145701

Clinical Data

This intervention maps to 17 entities in the Healos knowledge graph.

17
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
14
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.